VEGF-Trap has longer duration of effect

1 view

Skip to first unread message

MyVisionTest

unread,

Oct 26, 2009, 9:36:39 PM10/26/09

to Google Groups

Data from the extension study of VEGF-Trap suggest clinically
significant improvements in vision with low dosing burden and a
favorable safety profile, according to a speaker at the American
Academy of Ophthalmology meeting.

In the CLEAR-IT 2 extension study, 117 patients were followed with
as-needed therapy with VEGF-Trap (Aflibercept, Regeneron), which binds
the two key VEGF receptors in the eye and may offer improved affinity,
duration and penetration than current agents, David S. Boyer, MD, said
during the joint meeting of the American Academy of Ophthalmology and
the Pan-American Association of Ophthalmology.

In the study, patients received three monthly loading doses, followed
by 21 months of PRN therapy. Overall, 9% of patients required no
additional therapy in the as-needed therapy phase and 50% required
less than 4 doses. According to Dr. Boyer, the mean number of doses
delivered was 4.6 per patient over the 2 years of study.

Patients gained 7.3 letters of visual acuity during the initial
3-month loading phase that increased to 8.4 letters through 12 months.
At 18 months, patients had a +7.1 letter gain and +6.1 letters at 24
months, Dr. Boyer said.

OSN Supersite

http://www.osnsupersite.com/view.aspx?rid=44920

======================
ABOVE IS A PLAIN TEXT REPRODUCTION OF A NEWS STORY THAT APPEARS ON
MYVISIONTEST.COM. ANY HYPERLINKS, IMAGES, TABLES, OR OTHER
ENHANCEMENTS HAVE BEEN REMOVED. TO VIEW THE ORIGINAL VISIT THE BELOW
LINK.